Zacks.com submits:
Mylan Inc. (MYL) has entered into an agreement with Takeda Pharmaceutical for two type II diabetes drugs – Actoplus Met and Actos, which recorded 2009 sales of $459 million and $3.4 billion, respectively. 
Following the agreement, Mylan will be able to launch the generic versions of Actoplus Met on Dec 14, 2012 and Actos on Aug 17, 2012 or earlier under certain circumstances. The company expects to be eligible for 180 days of marketing exclusivity for both the drugs on approval.